WO2008061480A1 - Novel mangiferin calcium salts, the method for its preparation and its use - Google Patents
Novel mangiferin calcium salts, the method for its preparation and its use Download PDFInfo
- Publication number
- WO2008061480A1 WO2008061480A1 PCT/CN2007/071112 CN2007071112W WO2008061480A1 WO 2008061480 A1 WO2008061480 A1 WO 2008061480A1 CN 2007071112 W CN2007071112 W CN 2007071112W WO 2008061480 A1 WO2008061480 A1 WO 2008061480A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- mangiferin
- diabetic
- preparation
- solution
- Prior art date
Links
- 0 *c(c(*)c1)cc(C(c2c3*)=O)c1Oc2cc(*)c3[Cn] Chemical compound *c(c(*)c1)cc(C(c2c3*)=O)c1Oc2cc(*)c3[Cn] 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
Abstract
The present invention provides a mangiferin calcium having the following formula and its preparation and use. The said mangiferin calcium can lower plasma insulin, glucose, lipid, and also can improve the solubility, oral bioavailability and insulin sensitivity of mangiferin.
Description
NOVEL MANGIFERIN CALCIUM SALTS5THE METHOD FOR ITS PREPARATION AND ITS USE
FIELD OF THE INVENTION
The present invention relates to novel mangiferin calcium and their preparation methods and the use as the insulin sensitizer for diabetes and diabetic complication. BACKGROUND OF THE INVENTION
Insulin resistance (IR) refers to a series of pathologic and clinical syndrome is resulted from that the response of insulin target organs or tissues to the biological effects of insulin lowered or lost. Numerous studies show that insulin resistance exists in the whole process of type 2 diabetes,it is a marked characteristic of type 2 diabetes. The IR at the core, can lead to hyperglycemia, hypertension, microalbuminuria, inflammation, high fibrinolysis, dyslipidosis, endothelial dysfunction, and atherosclerosis and cardiovascular disease. Therefore, by increasing insulin action, improve insulin receptor sensitivity, research and development of insulin sensitizer in the treatment of diabetes and diabetic complication in recent years has become the hotspot.
At present, the most insulin sensitizers that are on the market are expensive or have some adverse reactions, caused by poor compliance of patients. Therefore research and development of insulin sensitizers of low cost> high efficiency and low toxicity have important clinical significance and market value.
Mangiferin, a natural polyphenol is from Anemarrhena asphodeloides Bge.or the leaf of Mangifera indical, Anacardiaceae mango tree, the leaf> fruit or bark of Mangifera persiciforma CY Wu et T.L.Ming. , gentian plants Northeast gentian, Swerita musstii Franch, or Pyrrosia clavata(Bak.)Ching.. molecular weight: 422, structural formula : Ci9Hi8On,
Mangiferin is a natural antioxidants. The pharmacological study shows Mangiferin has a variety of biological activity, such as anti-oxidation, anti-tumor, anti-bacterial, anti-viral, hypoglycemic, hypolipidemic, anti-inflammatory, choleretic,
immunomodulation, etc.. Mangiferin can lower the blood glucose and lipid levels of diabetic rats or mice by oral or intraperitoneal injection, its potential mechanism for hypoglycemic is by increasing insulin sensitivity [Miura TJchiki H,Hashimoto I,et al.Antidiabetic activity of a xanthone compound , mangiferin.Phytomedicine,2001,8(2):85-87 ] . But mangiferin exists defects in solubility > the bioavailability and absorbability of the body. SUMMARY OF THE INVENTION
In the course of present invention carrying out ,we have obtained a series of salt compounds of mangiferin, which we have applied patent [ application No.CN200610036739.3 ; invention title: mangiferin salts and the method for preparation and their use] . In that patent application we expatiated mangiferin salts can improve the solubility and oral bioavailability of mangiferin .As we research on pharmacology actives of increasing insulin sensitivity for these mangiferin salts , we found surprisedly the mangiferin calcium not only improve the solubility and oral bioavailability of mangiferin, but also increase insulin sensitivity more strongly than mangiferin,
Technology project: In present invention ,mangiferin calcium have the general formula ( I ) :
( I ) where n is 1 or 2 and m is 1 or 2.
When n is 2 and m is l,the mangiferin calcium have general formula ( II ):
Where any one radicel of R1,R2,R3 and R4 is oxygen ion, the other radicels
are hydroxyl. The priority elective compound have general formula (III):
When n is 1 and m is l,the mangiferin calcium have genenral formula (IV):
Where any two radicel of R1,R2,R3 and R4 are oxygen ion, the other radicels are hydroxyl.
When n is 1 and m is 2, the mangiferin calcium have general formula (V):
The present invention provides a method for preparation mangiferin calcium:
In present invention, sodium (or potassium) mangiferin is obtained first, then sodium (or potassium) mangiferin reacted with water-solubility calcium salt, and come into being mangiferin calcium . The method for preparation is follow as:
©mangiferin is suspended in menstruum, the solution of alkaline sodium (or potassium) is added slowly into the menstruum while mixing round until the solution is clear ,then the reaction solution is filtrated, crystal menstuum is added into the reaction solution, mixing round adequately . A lot of deposition is come into being , the reaction solution is filtrated to get the depositon ,the solid substance is heated up no excess 60 °C to dry . The yellow substance is sodium (or potassium) mangiferin.
©sodium (or potassium) mangiferin is dissolved into water appropriated
concentration, then water-solubility calcium salt solution of appropriated concentration is added slowly into it while mixing round. The reaction solution is mixed round continuely to reacte completely. A lot of deposition is come into being in solution. The reaction solution is filtrated to get the depositon. This deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium.
In the method of preparation as defined above, the mol ratio of mangiferin and alkaline sodium (or potassium) is 1 :0.4-1.1.
In the method of preparation as defined above, the mol ratio of sodium (or potassium) mangiferin and water- solubility calcium salt is 1 : 0.4-1.
In the method of preparation as defined above, the alkaline sodium (or potassium) is single salt or mixture which is for example sodium carbonate or sodium bicarbonate or potassium carbonate or potassium bicarbonate or sodium acetate or potassium acetate etc. .
In the method of preparation as defined above, the menstruum is mixture , which water mixed with one or more than two kind of organic solvent for example ethanol or methanol or acetone which can dissolve water at discretion . The ratio of water is 10-90% (v/v).
In the method of preparation as defined above, the crystal menstruum is single organic solvent or mixture which is for example ethanol , acetone , ethyl acetate or chloroform , dichloromethane and the other .
In the method of preparation as defined above, the water-solubility calcium salt is single salt or mixture which is for example calcium chloride, calcium gluconate , calcium lactate,calcium valerate , calcium glycerophosphate etc..
The mangiferin calcium in present invention can be obtained by reaction mangiferin with alkaline calcium compounds. The method for preparation is follow as:
Mangiferin is dissolved into appropriate solvent, and alkaline calcium compounds are dissolved into appropriate solvent , the alkaline solution is added into the mangiferin solution slowly while mixing round .Appropriate quantity solvent is added into reaction solution ,a mass of yellow deposition appeared . The solution is filtrated to get deposition, the deposition is heated up no excess 60 °C to dry. The yellow green solid substance is calcium salt of mangiferin.
In the method for preparation as defined above, the mol ratio of mangiferin and alkaline calcium compounds is 1 :0.5-2.
In the method for preparation as defined above, the alkaline calcium compound is single or mixture from which is inorganic calcium compounds or organic calcium compounds for example calcium hydroxide, calcium bicarbonate, calcium gluconate, calcium citric acid, calcium malic acid , calcium lactate ,calcium acetate, calcium vitamin C etc. .The priority elective compound is calcium hydroxide .
In the method for preparation as defined above, the solvents is single or mixture from which is the water solvent, dimethyl sulfoxide (DMSO), methanol, ethanol, acetone and other solvents.
In the process of research, we found phenomenon as follow :
1 > The water solution of mangiferin calcium which reacted mangiferin with calcium hydroxide is unstable, it changes much in 2 hours. The reaction of mangiferin with other alkaline calcium like calcium bicarbonate or calcium gluconate or calcium citric acid malic acid or calcium lactate or calcium acetate is difficult because they are alkalescent. The productivity is very low.
2> If mangiferin and calcium chloride are put together into water several ten days or heated up ten hours along, a little mangiferin calcium come into being in solution ,which can be detected by HPLC, but these substance is too little to have industry value .
3 > Sodium (or potassium) mangiferin is come into being first; then sodium (or potassium) mangiferin reacted with water-solubility calcium salt, and come into being mangiferin calcium. The mangiferin calcium which is obtained by this method is stability , and the productivity is high.
Analysis about the four hydroxyl of mangiferin:
6,7-two hydroxyl which conclude each other can't reacte with alkalescent sodium (or potassium) for their acidity is too weak . 1- hydroxyl which conclude with 9-carbonyl can't reacte with alkalescent sodium (or potassium) too for it is weak acid . 3- hydroxyl can reacte with alkalescent sodium (or potassium) for its acidity is stronger than 6,7-two hydroxyl and 1- hydroxyl. 3- hydroxyl's acidity is not strong enough to reacte with alkalescent calcium salt like calcium bicarbonate or calcium gluconate or calcium citric acid or calcium lactate or calcium acetate to come into mangiferin calcium. The alkalescence of calcium hydroxide is too strong which can reacted with any hydroxyl of mangiferin. It is difficult to obtain single compound for the position of electropositive is indetermination ,and the compounds are unstability too.
Through the analysis and reseach above all, the method which sodium (or
potassium) mangiferin is come into being first, then sodium (or potassium) mangiferin reacted with water-solubility calcium salt,and come into being mangiferin calcium is most excellent in the invention.
In the invention mangiferin calcium maybe crystal water compounds,the number of crystal water may be 1-8.
The substance in present invention may be mangiferin analog calcium for example neomangiferin calcium or ramification of mangiferin venter structure calcium.
Mangiferin calcium may be prepared to clinic acceptable formulations with pharmaceutical acceptable auxiliary material .The formulations may be oral formulations or external formulations and injection formulations etc., for example tablets, capsules ,gentle capsules, granules .pills ,oral solution ,oral suspension, gels and powder for injection etc. .
The present invention also provides that mangiferin calciums [structures are ( I ) — ( V ) ] are used as insulin sensitizers. These insulin sensitizers can also be use as hypoglycemic drugs, hypolipidemic drugs. As insulin sensitizers can be used for prevention and treatment of type 2 diabetes and diabetic chronic complications. Diabetic chronic complications refers to diabetic macrovascular disease and diabetic microangiopathy, diabetic neuropathy, diabetic foot, diabetic maeulopathy, diabetic cataract, diabetic glaucoma, refractive changes, iris and ciliary body diseases. As hypolipidemic drugs can be used for prevention and treatment hyperlipidemia.
The present invention provides the effective dose range of mangiferin calcium is 10-80 mg/kg/day for the rats when mangiferin calcium is used as insulin sensitizers, In accordance with the different types of animals dose conversion formula discount to the human body for 100-800mg/day/person by oral administration, three times per day. Because of the difference between animals and the human body, so the adjustments of the actual clinical application dose can be allowed.
The invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention. EXAMPLES
The mangiferin in the invention can buy from market (the factory which have the correspond equipment can produce,for example Guangxi changzhou natural product Ltd.), mangiferin can separate from Rhizoma Anemarrhenae or leaves of Mangifera indica L and other plants which have mangiferin . The reagent in present invention
like sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium acetate, potassium acetate, calcium bicarbonate, calcium gluconate, ethanol, acetone, ethyl acetate, chloroform, dichloromethane etc. can buy from market. The standard mangiferin and neomangiferin buy from China national institute for the control of pharmaceutical and biological products . Example 1 : Preparation of mangiferin and neomangiferin
100kg Rhizoma Anemarrhenae are extracted by means of aqueous 80% ethanol two times at the temperature of 80 °C . The combined extracts are evaporated. After the filtration the evaporated extract is placed into macfofeticulaf resin column to adsorb, then the macfofeticulaf resin column is washed with water adequately. Neomangiferin is unfixed by aqueous 20% ethanol, the solution is concentrated to obtained the crude neomangiferin. Mangiferin is unfixed by aqueous 40% ethanol, the solution is concentrated to obtained the crude mangiferin . The crude mangiferin is recrystallized from a mixture of solvents—dioxane-water to get pure mangiferin . The crude neomangiferin is recrystallized from a mixture of solvents—dioxane to get pure neomangiferin . The mangiferin samples is distinguished with mangiferin control ,we acknowledged the samples are mangiferin. The purity of mangiferin is 90.5% detected by HPLC. The neomangiferin samples is distinguished with neomangiferin control, we acknowledged the samples are neomangiferin. The purity of neomangiferin is 91.2% detected by HPLC . Example 2 : Preparation of sodium mangiferin
Mangiferin 42.2(0. lmol) is suspend in the mixture of water 100ml and ethanol 900ml in reactor ,mixing round adequately. Sodium carbonate 5.30g(0.05mol) is dissolved in water , the concentration is 0.1 %( w/v) . The solution of sodium carbonate is added slowly into the mangiferin suspended solution while mixing round until the solution is clear , then the reaction solution is filtrated, appropriate quantity actone is added into the reaction solution, mixing round adequately . A lot of deposition is come into being , the reaction solution is filtrated to get the depositon, the solid substance is heated up not excess 60 °C to dry .the yellow substance is sodium mangiferin. Its weight is 34.5g, the productivity is 81.7%. The purity of sodium mangiferin is 95% detected by HPLC.
Compound identify:
13CNMR(DMSO-d6) (δppm): 161.7(C-I), 106.9(C-2), 146.6(C-3), 93.2(C-4), 155.9 ( C-4a), 100.6(C-4b), 102.7(C-5), 153.7(C-6), 177.5(C - 9), 73.5(C-I '), 70.5(C-2'), 79.0(C-3'), 70.3(C-4') , 81.2(C-5'), 61.1(C-6').
13CNMR data of mangiferin in reference document [ ^ic^g , fj§^>β . M Ht^P M^MΕ^MfrM^fø&fe. MΨΨM, 1997; 32 (6): 473-475] :
13CNMR(DMSO-d6) (δppm): 161.6(C-I), 107.3(C-2), 163.6(C-3), 93.9(C-4), 156.1 ( C-4a), 101.2(C-4b), 102.5(C-5), 153.6(C-6), 143.7(C-7), 108.1(C-8), 118.7(C-8a), 150.7(C-8b), 179.0(C - 9), 73.0(C-I '), 70.5(C-2'), 78.8(C-3'), 70.3(C-4') , 81.3(C-5'), 61.4(C-6').
According to the reference literature of mangiferin structure identify [ ^TJC ^H , w&m.
MΨΨU, mi-, 32 (6): 473
—475 ] , the sodium mangiferin 13CNMR data reveal: The chemical shift of C-3 displace to high-frequency magnetic field markedly, The chemical shift of C-2, C-4, C-4a, C-4b and C-9 displace to high-frequency magnetic field too.
According the sodium mangiferin 13CNMR data and the process of sodium mangiferin preparation, we deduce the sodium is linked to the position C-3 hydroxy of mangiferin . Example 3 : Preparation of sodium mangiferin
Mangiferin 42.2(0. lmol) is suspend in the mixture of water 900ml and ethanol 100ml in reactor, mixing round adequately. Sodium bicarbonate 9.24g(0.11mol) is dissolved in water ,the concentration is 5%( w/v) . The solution of sodium bicarbonate is added slowly into the mangiferin suspended solution while mixing round until the solution is clear , then the reaction solution is filtrated, appropriate quantity ethanol-ethyl acetate(l :1.5 v/v) is added into the reaction solution, mixing round adequately . A lot of deposition is come into being, the reaction solution is filtrated to get the depositon, the solid substance is heated up no excess 60 °C to dry . The yellow substance is sodium mangiferin. Its weight is 32.96g, the productivity is 78.1%. The purity of sodium mangiferin is 92% detected by HPLC. Example 4: Preparation of potassium mangiferin
Mangiferin 42.2(0. lmol) is suspended in the mixture of water 300ml and ethanol 700ml in reactor, mixing round adequately. Potassium carbonate 5.52g(0.04mol) is dissolved in water ,the concentration is 0.2%( w/v) . The solution of potassium carbonate is added slowly into the mangiferin suspended solution while mixing round until the solution is clear, then the reaction solution is filtrated, appropriate quantity ethanol- chloroform (4:1 v/v) is added into the reaction solution, mixing round adequately . A lot of deposition is come into being, the reaction solution is filtrated to get the depositon, the solid substance is heated up no excess 60 °C to dry. The yellow substance is potassium mangiferin. Its weight is 35.19g, the
productivity is 83.4%. The purity of potassium mangiferin is 93% detected by HPLC.
Example 5 : Preparation of potassium mangiferin
Mangiferin 42.2(0. lmol) is suspended in the mixture of water 400ml and ethanol 1600ml in reactor ,mixing round adequately. Potassium bicarbonate 10.0g(0. lmol) is dissolved in water , the concentration is 0.1%( w/v) . The solution of potassium bicarbonate is added slowly into the mangiferin suspended solution while mixing round until the solution is clear , then the reaction solution is filtrated, appropriate quantity ethanol-dichloroform (7:1 v/v) is added into the reaction solution, mixing round adequately . A lot of deposition is come into being , the reaction solution is filtrated to get the depositon, the solid substance is heated up no excess 60 °C to dry .The yellow substance is potassium mangiferin . Its weight is 34.65g, the productivity is 82.1%. The purity of potassium mangiferin is 94% detected by HPLC. Example 6: Preparation of mangiferin calcium
Sodium mangiferin 4.44g(0.01mol) is dissolved into 1500ml water, calcium chloride 0.44g(0.004mol) is dissolved in 100ml water, calcium chloride solution is added slowly into sodium mangiferin solution while mixing round . mixing round until it reacte completely . A lot of deposition is come into being in solution. The reaction solution is chilled in 4°C more than 3hours, then filtrated to get the depositon .The deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium. Its weight is 3.07g, the productivity is 69.2%. The purity of mangiferin calcium is 98.5% detected by HPLC.
Compound identify:
ESI-MSm/z: 442[M/2+H] \ 423[Mmgf+H]+, we conjecture the molecular weight of the compound is 882; IR(KBr)cm~ : 3411 , 3180 ( shoulder , OH) ,2926,2900,1650, 1620(conjugate carbonyl),1474(phenyl).
The 1HNMR(DMSO-d6) ( δppm) : the end proton of glucose signal is at 4.60(lH,d, J=9.8 Hz) ,and it exist a beta-glycoside. Three phenyl proton signal is at 6.23(lH,s),6.32(lH,s) and 7.09(lH,s).
13CNMR(DMSO-d6)(δppm): 161.5(C-l),106.8(C-2),146.9(C-3),93.1(C-4),155.8 (C-4a), 100.8(C-4b), 103.1(C-5), 153.4(C-6), 177.5(C~9) , 73.4(C-I ') , 70.4(C-2') , 79.0(C-3') , 70.2(C-4'), 81.2(C-5') , 61.1(C-6').
According to the reference literature of mangiferin structure identify [ ^TJC ^m ■> Wkm~ .
MΨΨU, 1997; 32 (6): 473 —475 ] , the sodium mangiferin 13CNMR data reveal: The chemical shift of C-3
displace to high-frequency magnetic field markedly, The chemical shift of C-2> C-4> C-4a> C-4b and C-9 displace to high-frequency magnetic field too.
According the sodium mangiferin 13CNMR data and the process of preparation of mangiferin calcium, we deduce the calcium is linked to the position C-3 hydroxy of mangiferin .
The structure of mangiferin calcium is follow as:
Example 7: Preparation of mangiferin calcium
Sodium mangiferin 4.44g(0.01mol) is dissolved into 1000ml water, calcium gluconate 2.15g(0.005mol) is dissolved in 150ml water, calcium gluconate solution is added slowly into sodium mangiferin solution while mixing round , mixing round until it reacte completely. A lot of deposition is come into being in solution. The reaction solution is chilled in 4°C more than 3hours, then filtrated to get the depositon .this deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium. Its weight is 3.18g, the productivity is 71.7%. The pure of mangiferin calcium is 98.4% detected by HPLC. Example 8: Preparation of mangiferin calcium mangiferin potassium 4.6g(0.01mol) is dissolved into 500ml water, calcium chloride l.llg(O.Olmol) is dissolved in 300ml water, calcium chloride solution is added slowly into mangiferin potassium solution while mixing round , mixing round until it reacte completely. A lot of deposition is come into being in solution. The reaction solution is chilled in 4°C more than 3hours , then filtrated to get the depositon . This deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium. Its weight is 3.14g, the productivity is 68.3%. The pure of mangiferin calcium is 98.6% detected by HPLC. Example 9: Preparation of mangiferin calcium mangiferin 4.2g(0.01mol) is dissolved into 50ml DMSO, calcium hydroxide 0.37g(0.005mol) is dissolved in 80g glycerol, calcium hydroxide solution is added slowly into mangiferin solution while mixing round, mixing round until it reacte completely. Appropriate quantity ethanol is added into the reaction solution, mixing
round adequately. A lot of deposition is come into being in solution. The reaction solution is filtrated to get the depositon . This deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium. Its weight is 3.8g, the productivity is 90.4%. Example 10: Preparation of mangiferin calcium mangiferin 4.2g(0.01mol)is dissolved into 80ml DMSO, calcium hydroxide 1.48g(0.02mol) is dissolved in 20Og glycerol, calcium hydroxide solution is added slowly into mangiferin solution while mixing round , mixing round until it reacte completely. Appropriate quantity ethanol is added into the reaction solution, mixing round adequately . A lot of deposition is come into being in solution. The reaction solution is filtrated to get the depositon. This deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium. Its weight is 3.83g, the productivity is 91.2%. Example 11 : Preparation of mangiferin calcium mangiferin 4.2g(0.01mol)is dissolved into 80ml DMSO, calcium citric acid 5.7g(0.01mol) is dissolved in water, mangiferin solution is added slowly into calcium citric acid solution while mixing round , mixing round adequately. The reaction solution is filtrated, the depositon is washed with water adequately, the solution is concentrate to appropriate quantity, then ethanol is added into the solution, deposition is come into being in solution. The reaction solution is filtrated to get the depositon. This deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium. Its weight is 0.46g, the productivity is 11.1%. Example 12: Preparation of neomangiferin calcium
Neomangiferin 58.2(0.1 mo 1) is suspended in the mixture of water 200ml and ethanol 600ml in reactor , mixing round adequately. Sodium carbonate 10.6g(0.1mol) is dissolved in water ,the concentration is 0.3%( w/v) . The solution of sodium carbonate is added slowly into the neomangiferin suspended solution while mixing round until the solution is clear , then the reaction solution is filtrated, appropriate quantity ethanol- Ethyl acetate (1 :1 v/v) is added into the reaction solution, mixing round adequately . A lot of deposition is come into being , the reaction solution is filtrated to get the depositon, the solid substance is heated up no excess 60 °C to dry . The yellow substance is sodium neomangiferin. Its weight is 41.55g, the productivity is 71.4%.
Sodium neomangiferin 6.04g(0.01mol) is dissolved into 1000ml water, calcium chloride l.lg(O.Olmol) is dissolved into 150ml water, the calcium chloride solution is
added slowly into sodium neomangiferin solution while mixing round . Mixing round until it reacte completely. A lot of deposition is come into being in solution. The reaction solution is chilled in 4°C more than 3hours ,then filtrated to get the depositon . This deposition is heated up no excess 60 °C to dry. The yellow green solid substance is neomangiferin calcium. Its weight is 3.94g, the productivity is 65.3%. The pure of neomangiferin calcium is 98.4% detected by HPLC. Example 13: Preparation of mangiferin calcium capsules
The formulation is as follow : mangiferine calcium 40Og carboxymethyl cellulose 30O g pregelatinized starch 300 g the total is 10000 capsules.
Mangiferine calcium is obtained by the method of example 5 which is shattered into exiguous powder, mangiferine calcium and pregelatinized starch and carboxymethyl cellulose are put into together mixing round uniformity . Appropriate bond is spray in the powder to make soft material ,which is cranked out granule . The granule is dried and then is put into capsules, 10000 capsules are prepared . There is 40mg mangiferin calcium in every capsule. Example 14: Preparation of mangiferin calcium tablets
The formulation is as follow : mangiferine calcium 50Og microcrystalline cellulose 200 g starch 300 g
The total is 10000 tablets. mangiferine calcium is obtained by the method of example 6 which is shattered into exiguous powder, mangiferine calcium and starch and microcrystalline cellulose are put into together mixing round uniformity . Appropriate bond is spray in the powder to make soft material ,which is cranked out granule . the granule is dried and then tablets are pressed by tablet pressed machine .10000 tablets are prepared . There is 50mg mangiferin calcium in every tablet. Example 15: Preparation of mangiferin calcium granule
The formulation is as follow : mangiferin calcium lOOg carboxymethyl cellulose 300 g pregelatinized starch 300 g xylose 50Og
The total is 100Og.
Mangiferin calcium is prepared by the method of example 5 which is shattered into exiguous powder, mangiferin calcium and pregelatinized starch and carboxymethyl cellulose and xylose are put into together mixing round uniformity .
Appropriate bond is spray in the powder to make soft material ,which is cranked out granule . The granule is dried .100Og granule is prepared . there is lOOmg mangiferin calcium in every gram. Example 16: Preparation of mangiferin calcium gel
The formulation is as follow : mangiferine calcium 1Og tween80 2g carbomer940 1Og sodium hydroxide 4g ethanol 80g
The surplus is distilled water
The total is 100Og.
Carbomer940 and Tween80 are mixed into water (solution 1), sodium hydroxide is dissolved in 100ml water and added into solution 1, Gel matrix is obtained. Mangiferine calcium exiguous powder is dissolved in mixture of water and ethanol (solution 2) .solution 2 is added into gel matrix and mixed uniformity.The gel is Plus distilled water to 1000 g, mixing uniformity .That is mangiferin calcium gel. Example 17: Preparation of mangiferin calcium powder for injection
The formulation is as follow : mangiferine calcium 1Og mannitol 4Og the surplus is distilled water
The total is 2000ml.
Mannitol is added into 1500ml water for injection in appropriate containers, Activated carbon for injiection is added into the solution and heated up to 80 °C while mixing round 30min,then the solution is filtrated by microporous membrane of 0.22μm (solution 1). Mangiferine calcium exiguous powder is dissolved in solution 1, Plus water for injection to 2000ml, then the solution is filtrated by Microporous Membrane of 0.22μm, the solution is separated into bottles , every bottle have lOmg mangiferin calcium, all samples are freezed-drying. Stopers are pushed down after Freeze-drying, the bottles are airproof by covers, then stickers are pasted and packed up. That is mangiferin calcium powder for injection. The solubility of calcium:
5mg mangiferin powder which is weighed up accurately is put into 50ml distilled water , the solution is shaked acutely 30 second every 5 minutes .The mangiferin can't dissolved in 30 minutes .The water solubility of mangiferin is less than 0.1mg/ml . Mangiferin is hardly solubility substance in water.
50mg mangiferin calcium powder which is obtained by the method for preparation of example 6 and weighed up accurately is put into 50ml distilled
water ,the solution is shaked acutely 30 second every 5 minutes,The mangiferin calcium can dissolve in 30 minutes. lOOmg mangiferin calcium powder which is obtained by the method for preparation of example 6 and weighed up accurately is put into 50ml distilled water , the solution is shaked acutely 30 second every 5 minutes. The mangiferin calcium can not dissolve completely in 30 minutes.
The water solubility of mangiferin calcium is more than lmg/ml . Mangiferin is tiny solubility substance in water.
The Pharmacokinetics of mangiferin and mangiferin calcium after oral administration
1 > the confect of drug solution
Mangiferin is suspended in Carboxymethyl cellulose sodium solution which concentration is one percent,the mangiferin concentration is 10mg/mL,which is sample A.
Mangiferin calcium is suspended in Carboxymethyl cellulose sodium solution which concentration is one percent, the mangiferin concentration is 10mg/mL,which is sample B. The mangiferin calcium is obtained by the method for preparation of example 6.
2> oral administrated project
All rats were fasted for 16 hours, free drinking water. The rats are oral administrated separately sample A and sample B, which dose is 100mg/kg . The rats were taken whole blood in 5 minutes before oral administrated and 15 min ,30 min,45 min,60 min,90 min, 120 min, 180 min,240 min,300 min,360 min,480 min after oral administrated. Serum is separated from these blood samples.
3 > Serum Sample treatment
Serum Samples are extracted accurately 0.2ml into centrifuge tubes separately, then 40μL cold trichloroactic acid solution which concertration is ten percent is added into centrifuge tubes separately. The samples are whorled 3 minutes , then centrifuged 12000 r / min for 10 minutes , 120μl the up layer solution are extracted from centrifuge tubes and put into sample bottles separately. All the samples are detected by HPLC.
Apparatus: Angilent 1100 HPLC (American Agilent Co.),include G1312A dual pump G 1313 A Auto-Sampler.
Chromatographic conditions:
Chromatographic column : discover ODS column (250mm><6mm,5μm);
The mobile phase: Acetonitrile-0.1%H3PO4 water (13:87 v/v)
Velocity of flow :1.0 ml/min.Detection Wavelength :254nm.
Column temperature: 30°C
4> Results:
According to the data (Table 1 ) ,the Concentration of drug in plasma of oral administrated mangiferin calcium is higher than oral administrated mangiferin . The Bioavailability of mangiferin calcium is better than mangiferin.
Table 1 The Pharmacokinetics parameter of mangiferin calcium and mangiferin parameter mangiferin mangiferin calcium
Cmax/μg/ml 14.8±0.5 48.3±0.6
Ti/2β (min) 45.7±8.3 61.4±7.7
AUCo-∞/μg.h/ml 1864.1±275.2 3469.2±359.3
Efficacy in STZ model 1 > Materials
Mangiferin calcium are prepared in accordance with the method of preparation of example 9. Mangiferin are prepared in accordance with the method of preparation of example 1. Rosiglitazone Hydrochloride tablets were purchased from Zhejiang wanma pharmaceutical Co., Ltd. Mangiferin and mangiferin calcium salts were suspended with 3 %o sodium carboxymethyl cellulose.
Normal female wistar rats(SPF, 3 months age, 180— 20Og) were purchased from Hainan provincial peoples hospital experimental Animal Center. The animals were kept in a room temperature(25~28°C) with free access of food and water. A light-dark cycle(6 a.m and 6 p.m)was strictly enforced. High fat chow is composed of 55% basic chow, 2% protein, 16% fat, 27% white sugar. 2> Method
Model: After the rats were fasted for 12 hours, the rats are injected 30-35mg/kg streptozotocin (STZ) solution once by tail vein. STZ solution is prepared to 2% concentration with 0.1 mmol / L, pH 4.4 citrate - sodium citrate buffer before use. The model rats were weighed > taked out tail vein blood > tested blood glucose when the Model is done after 14 days after fasting for 12 hours, then injected 20% glucose solution (2mg/kg) by intraperitoneal, determined blood glucose in 0.5h, Ih, 2h. The rats whose glucose tolerance were abnormal were bringed into experiments. Normal wistar rats were fed normal chow, model rats were fed high fat chow.
Experimental group : normal wistar rats group(n= 10) ; after Diabetes model is
succeed, the rats were randomly divided into 7 groups: Diabetes model group(w = 10 ); mangiferin groups (20> 40 > 80mg/kg,each 10 rats) ; mangiferin calcium groups ( 10> 20 > 40mg/kg,each 10 rats) ; Rosiglitazone Hydrochloride group [3mg/kg, n = 10] o Test samples or vehicle control was given orally for 8 weeks. Diabetes model group and normal group were given vehicle.
Measurements:
Determination of insulin sensitivity(Glucose infusion rate): Using glucose clamp technique, in accordance with Konglingdong'method [
^,2006,26:76-79 ] in the treatment of eight weeks.
Determination of plasma glucose and lipid: Rats were taken whole blood after killed, then serum was separated, determined plasma glucose(GLU), insulin(INS), triglycerides(TG) and free fatty acids(FFA).
GLU and TG levels were determined using GF-D800 semi-auto chemist which was purchased from Shandong Gaomi Caihong Analytical Instrument Co., Ltd. Free fatty acids were determined using copper colorimetric determination. The kits for Determination of free fatty acids were purchased from Nanjing Jiancheng Bioengineering Institute. Insulin: radioimmunoassay(RIA), γ counter counts, insulin RIA Kit was purchased from Shandong Weifang City three-dimensional (3 V) Biological compny.
Statistics: The results have been calculated as mean±SD ( #±SD) and compareisons of the data have been done by t-test.
3> Results
20mg/kg mangiferin does not significantly improve GLU > TG > FFA > INS> Glucose infusion rate in diabetic rats. 10mg/kg mangiferin calcium can significantly improves GLU > TG > FFA > INS> Glucose infusion rate in diabetic rats and has a significant dose-effect relationship(Table 2).
These results suggest that mangiferin calcium can improve the solubility > oral bioavailability and pharmacological activity of mangiferin because the effective doses of mangiferin calcium are greatly reduced than mangiferin. Efficacy in GK model 1 > Materials
Mangiferin calcium are prepared in accordance with the method of preparation of example 6. Mangiferin are prepared in accordance with the method of preparation of example 1. Rosiglitazone Hydrochloride tablets were purchased from Zhejiang
wanma pharmaceutical Co., Ltd. Mangiferin and mangiferin calcium were suspended with 3 %o sodium carboxymethyl cellulose before use.
Goto-Kakizaki rats(GK) ( 16 weeks age, 9 <$) were purchased from Shanghai SLAC laboratory animal Co., Ltd. <, The animals were kept in IVC cages with temperature(22°C). There are two rats in each cage. 2> Method
Experimental group: GK rats group(n=10); mangiferin groups (20> 40 > 80mg/kg,each 10 rats) ; mangiferin calcium groups ( 10> 20 > 40mg/kg,each 10 rats) ; Rosiglitazone Hydrochloride group[3mg/kg, n = 10] o Test samples or vehicle control was given orally for 30 days. GK rats group were given vehicle.
Measurements:
The blood specimens were taken by abdominal aorta at the end of the test. Plasma glucose(GLU), insulin(INS), triglycerides(TG)> total cholesterol (TC) > high density lipoprotein(HDL)> low density lipoprotein(LDL) were determined.
GLU > TC> TG> HDL and LDL levels were determined using GF-D800 semi-auto chemist which was purchased from Shandong Gaomi Caihong Analytical Instrument Co., Ltd. Insulin: radioimmunoassay(RIA), γ counter counts, insulin RIA Kit was purchased from Shandong Weifang City three-dimensional (3 V) Biological company.
Statistics: The results have been calculated as mean±SD ( #±SD) and compareisons of the data have been done by t-test. 3> Results
20mg/kg mangiferin does not significantly improve GLU > TC> TG > HDL and LDL and INS in diabetic GK rats. 10mg/kg mangiferin calcium can significantly improves HDL and LDL in diabetic GK rats. 20mg/kg mangiferin calcium can significantly improves GLU > TC> TG > HDL and LDL and INS in diabetic GK rats (Table3 ) .
These results suggest that mangiferin calcium can improve the solubility > oral bioavailability and pharmacological activity of mangiferin because the effective doses of mangiferin calcium are greatly reduced than mangiferin.
Table 2. Effect of the samples in STZ rats
Glucose infusion rate
Groups GLU(mmol/L) INS(μ IU/ml) TG(mmol/L) FFA(μmol/L)
(mg/kg-mm)
Normal group 6.37±0.39** 20.67±4.39** 1.38±0.1l" 1.08±0.12** 26.25±4.24**
Model group 11.43±0.42 37.39±3.56 3.62±0.37 1.88±0.20** 14.46±3.87**
Mangiferin group(20mg/kg) 10.56±0.38 33.42±3.79 3.42±0.41 1.79±0.24 15.75±3.69
Mangiferin group(40mg/kg) 8.45±0.23* 28.13±3.74* 2.82±0.22* 1.56±0.19* 18.32±3.89*
Mangiferin group(80mg/kg) 7.05±0.44** 24.35±3.46** 1.82±0.32** 1.29±0.34** 23.65±3.67**
Mangiferin calcium group(10mg/kg) 8.01±0.32* 27.63±3.46* 2.49±0.18* 1.54±0.23* 17.56±3.45*
Mangiferin calcium group(20mg/kg) 7.31±0.22** 23.57±3.68** 1.93±0.36** 1.28±0.14** 24.37±3.75**
Mangiferin calcium group(40mg/kg) 6.91±2.02** 20.53±4.42** 1.49±0.28** 1.13±0.18** 26.36±3.58**
Rosiglitazone group 7.49±2.18** 19.87±4.2l" 1.44±0.16** 1.25±0.13** 24.75±3.69**
Table 1 : compared with model group: p<0.05, p<0.01 o
Table 3. Effect of the samples in GK rats
Table 2: compared with GK group: *P<0.05; **P<0.01 ; ***P< 0.001.
Claims
CLAIMS :
1 > Novel mangiferin calcium having the formula ( I ) :
( I )
Where n is lor 2; m is lor 2»
2> The mangiferin calcium according to claim 1 , wherein : when n is 2, m is 1 , the mangiferin calcium have general formula ( II ):
Where any one radicel of R1,R2,R3 and R4 is oxygen ion, the other radicels are hydroxyl.
3 > The mangiferin calcium according to claim 2 , wherein : the mangiferin calcium have following formula (III):
4> The mangiferin calcium according to claim 1 , wherein : when n is 1 , m is 1 , the mangiferin calcium have general formula (IV):
(IV)
Where any two radicel of R1,R2,R3 and R4 are oxygen ion,the other radicels are hydroxyl.
5> The mangiferin calcium according to claim 1 , wherein : when n is 1 , m is 2, the mangiferin calcium have general formula (V):
6> A preparation of the mangiferin calcium according to claim 1 , wherein: the mangiferin calcium can be obtained by reaction mangiferin with alkaline calcium compounds .
7> The preparation of mangiferin calcium according to claim 6 , wherein: the mol ratio of mangiferin and alkaline calcium compounds is 1 :0.5-2.
8> The preparation of mangiferin calcium according to claim 6 , wherein:
Mangiferin is dissolved into appropriate solvent , and alkaline calcium compounds are dissolved appropriate solvent , the alkaline solution is added into the mangiferin solution while mixing round .Appropriate quantity solvent is added into reaction solution ,a mass of yellow deposition appeared . The solution is filtrated to get deposition, the deposition is heated up no excess 60 °C to dry. The yellow green solid substance is calcium salt of mangiferin.
9> The preparation of mangiferin calcium according to claim 6 , wherein: the alkaline calcium compound is single or mixture from which is inorganic calcium compounds or organic calcium compounds for example calcium hydroxide , calcium bicarbonate,
calcium gluconate, calcium citric acid, calcium malic acid ,calcium lactate , calcium acetate, calcium vitamin C. The priority elective compound is calcium hydroxide . 10> A preparation of the mangiferin calcium according to claim 3 , wherein: sodium (or potassium) mangiferin is obtained first, then sodium (or potassium) mangiferin reacted with water-solubility calcium salt, and come into being mangiferin calcium.
11 > The preparation of mangiferin calcium according to claim 10 , wherein: the mol ratio of mangiferin and alkaline sodium (or potassium) is 1 : 0.4-1.1.
12 > The preparation of mangiferin calcium according to claim 10 , wherein: the mol ratio of sodium (or potassium) mangiferin and water- solubility calcium salt is 1 : 0.4-1.
13 > The preparation of mangiferin calcium according to claim 10 , wherein:
©Mangiferin is suspended in menstruum, the solution of alkaline sodium (or potassium) is added into the menstruum while mixing round until the solution is clear ,then the reaction solution is filtrated, crystal menstuum is added into the reaction solution, mixing round adequately . A lot of deposition is come into being , the reaction solution is filtrated to get the depositon, the solid substance is heated up no excess 60 °C to dry . The yellow substance is sodium (or potassium) mangiferin.
©sodium (or potassium) mangiferin is dissolved into water appropriated concentration, then water-solubility calcium salt solution of appropriated concentration is added into it while mixing round. The reaction solution is mixed round until reacte completely. A lot of deposition is come into being in solution. The reaction solution is filtrated to get the depositon . This deposition is heated up no excess 60 °C to dry. The yellow green solid substance is mangiferin calcium. 14 > The preparation of mangiferin calcium according to claim 10 , wherein: the alkaline sodium (or potassium) is single salt or mixture which is sodium carbonate , sodium bicarbonate , potassium carbonate , potassium bicarbonate , sodium acetate and potassium acetate.
15 > The preparation of mangiferin calcium according to claim 10 , wherein: the water-solubility calcium salt is single salt or mixture which is calcium chloride , calcium gluconate , calcium lactate,calcium valerate , calcium glycerophosphate.
16> The preparation of mangiferin calcium according to claim 13 , wherein: the menstruum is mixture ,which water mixed with one or more than two kind of organic solvent for example ethanol or methanol or acetone which can dissolve water at discretion . The ratio of water is 10-90% (v/v).
17> The preparation of mangiferin calcium according to claim 13 , wherein: the crystal menstruum is single organic solvent or mixture which is for example ethanol , acetone , ethyl acetate or chloroform , dichloromethane and the other .
18> The mangiferin calcium according to claim 6-7, wherein : the mangiferin can be mangiferin analog calcium for example neomangiferin calcium or ramification of mangiferin venter structure calcium.
19> The mangiferin calcium according to claim 10-11 , wherein : the mangiferin can be mangiferin analog calcium for example neomangiferin calcium or ramification of mangiferin venter structure calcium.
20 > The mangiferin calcium according to claim 1-5 , wherein : mangiferin calcium can be crystal water compounds,the number of crystal water may be 1-8.
21 > A pharmaceutical composition, which comprises any effective amount of a mangiferin calcium as defined in claim 1-5, and a pharmaceutically acceptable auxiliary material o
22 > A pharmaceutical composition, which comprises an effective amount of a mangiferin calcium as defined in claim 3, and a pharmaceutically acceptable auxiliary material.
23 > A pharmaceutical composition according to claim 21 or 22, wherein: the formulations can be tablets, capsules, gentle capsules, granules, pills, oral solution, oral suspension, gels and powder for injection.
24 > A use of mangiferin calcium as defined in claim 1 — 5 , wherein: mangiferin calcium is used as insulin sensitizers.
25 > The use according to claim 24 , wherein: the insulin sensitizers can also be use as hypoglycemic drugs.
26 > The use according to claim 24 , wherein: the insulin sensitizers can also be use as hypolipidemic drugs.
27 > The use according to claim 24 , wherein: the insulin sensitizers can also be use for prevention and treatment of type 2 diabetes and diabetic chronic complications.
28 > The use according to claim 27 , wherein: the diabetic chronic complications refers to diabetic macrovascular disease and diabetic microangiopathy, diabetic neuropathy, diabetic foot, diabetic maeulopathy, diabetic cataract, diabetic glaucoma, refractive changes, iris and ciliary body diseases.
29 > The use according to claim 26 , wherein: mangiferin calcium as hypolipidemic drugs can be used for prevention and treatment hyperlipidemia.
30 > A use of mangiferin calcium as defined in claim 3 , wherein: mangiferin calcium is used as insulin sensitizers.
31 > The use according to claim 30 , wherein: the insulin sensitizers can also be use as hypoglycemic drugs.
32> The use according to claim 30 , wherein: the insulin sensitizers can also be use as hypolipidemic drugs.
33 > The use according to claim 30 , wherein: the insulin sensitizers can also be use for prevention and treatment of type 2 diabetes and diabetic chronic complications.
34 > The use according to claim 33 , wherein: the diabetic chronic complications refers to diabetic macrovascular disease and diabetic microangiopathy, diabetic neuropathy, diabetic foot, diabetic maeulopathy, diabetic cataract, diabetic glaucoma, refractive changes, iris and ciliary body diseases.
35 > The use according to claim 32 , wherein: mangiferin calcium as hypolipidemic drugs can be used for prevention and treatment hyperlipidemia.
36> A use of pharmaceutical composition as defined in claim 21 or 22, wherein: the pharmaceutical composition is used as insulin sensitizers.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/744,263 US8334267B2 (en) | 2007-11-22 | 2008-05-23 | Mangiferin calcium salts, the method for its preparation and its use |
| PCT/CN2008/001008 WO2009065287A1 (en) | 2007-11-22 | 2008-05-23 | Novel mangiferin calcium salts, the method for its preparation and its use |
| CN2008801157205A CN101848922B (en) | 2007-11-22 | 2008-05-23 | Novel mangiferin calcium salts, the method for preparation and use thereof |
| JP2010534342A JP5529745B2 (en) | 2007-11-22 | 2008-05-23 | Novel mangoglycoside calcium salt, process for producing the same and use thereof |
| EP08748529.8A EP2220103B1 (en) | 2007-11-22 | 2008-05-23 | Novel mangiferin calcium salts, the method for its preparation and its use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610123840 | 2006-11-24 | ||
| CN200610123840.2 | 2006-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008061480A1 true WO2008061480A1 (en) | 2008-05-29 |
Family
ID=39429405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2007/071112 WO2008061480A1 (en) | 2006-11-24 | 2007-11-22 | Novel mangiferin calcium salts, the method for its preparation and its use |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008061480A1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2220103A1 (en) * | 2007-11-22 | 2010-08-25 | Hainan Deze Drug Research Co., Ltd | Novel mangiferin calcium salts, the method for its preparation and its use |
| CN102161657A (en) * | 2010-02-24 | 2011-08-24 | 昆明制药集团股份有限公司 | Mangiferin crystal I and preparation method thereof |
| CN103193767A (en) * | 2012-01-05 | 2013-07-10 | 昆明制药集团股份有限公司 | Preparation method of 1,6,7-trihydroxy-3-methoxyl xanthone-2-C-beta-D-glucopyranoside |
| CN104473875A (en) * | 2014-11-20 | 2015-04-01 | 广西中医药大学 | Multi-element mangiferin solid dispersion as well as preparation method and application thereof |
| CN104558070A (en) * | 2013-10-14 | 2015-04-29 | 北京大学 | Chemical synthesis method of neomangiferin and intermediate compounds of neomangiferin |
| CN106491718A (en) * | 2016-12-16 | 2017-03-15 | 宁波沪信药物技术有限公司 | Produce compositionss from two kinds of plant amedica and application thereof |
| CN106581161A (en) * | 2016-12-16 | 2017-04-26 | 宁波沪信药物技术有限公司 | Composition for treatment and prevention of abnormal glucose metabolism and use thereof |
| CN106727964A (en) * | 2016-12-16 | 2017-05-31 | 宁波沪信药物技术有限公司 | Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof |
| WO2018006737A1 (en) * | 2016-07-04 | 2018-01-11 | 常州德泽医药科技有限公司 | Mangiferin-6-o-calcium salt and preparation method and use thereof |
| US10537604B2 (en) | 2016-07-19 | 2020-01-21 | Nektium Pharma, S.L. | Compositions for enhancing brain activity |
| US10874708B2 (en) | 2017-01-10 | 2020-12-29 | Nektium Pharma, S.L. | Compositions for reducing appetite and craving, increasing satiety, enhancing mood, and reducing stress |
| US11376294B2 (en) | 2016-07-19 | 2022-07-05 | Nektium Pharma S.L. | Mangiferin-containing compositions for improving sports performance |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1757648A (en) * | 2005-07-27 | 2006-04-12 | 李学坚 | Mangiferin derivatives and its prepn. method, and use as medicine |
| CN1919857A (en) * | 2006-08-24 | 2007-02-28 | 广西中医学院 | Preparation method and application of water-soluble mangiferin monosodium salt |
| CN101108869A (en) * | 2006-07-21 | 2008-01-23 | 徐广爱 | Mangiferin salt and method of preparing the same and use thereof |
-
2007
- 2007-11-22 WO PCT/CN2007/071112 patent/WO2008061480A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1757648A (en) * | 2005-07-27 | 2006-04-12 | 李学坚 | Mangiferin derivatives and its prepn. method, and use as medicine |
| CN101108869A (en) * | 2006-07-21 | 2008-01-23 | 徐广爱 | Mangiferin salt and method of preparing the same and use thereof |
| CN1919857A (en) * | 2006-08-24 | 2007-02-28 | 广西中医学院 | Preparation method and application of water-soluble mangiferin monosodium salt |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE CA [online] CHAKRABARTI D.K. ET AL.: "The disease cycle of mango malformation induced by Fusarium moniliforme var. subglutinans and the curative effects of mangiferin-metal chelates", Database accession no. (111:52348) * |
| J. PHYTOPATHOL., vol. 125, no. 3, 1989, pages 238 - 246 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2220103A4 (en) * | 2007-11-22 | 2010-10-27 | Hainan Deze Drug Res Co Ltd | Novel mangiferin calcium salts, the method for its preparation and its use |
| EP2220103A1 (en) * | 2007-11-22 | 2010-08-25 | Hainan Deze Drug Research Co., Ltd | Novel mangiferin calcium salts, the method for its preparation and its use |
| CN102161657A (en) * | 2010-02-24 | 2011-08-24 | 昆明制药集团股份有限公司 | Mangiferin crystal I and preparation method thereof |
| CN103193767A (en) * | 2012-01-05 | 2013-07-10 | 昆明制药集团股份有限公司 | Preparation method of 1,6,7-trihydroxy-3-methoxyl xanthone-2-C-beta-D-glucopyranoside |
| CN103193767B (en) * | 2012-01-05 | 2016-03-02 | 昆药集团股份有限公司 | The preparation method of the two benzene pyrrone-2-C-β-D-glucopyranoside of 1,6,7-trihydroxy--3-methoxyl group |
| CN104558070B (en) * | 2013-10-14 | 2017-10-24 | 北京大学 | The chemical synthesis process and midbody compound of Neomangiferin |
| CN104558070A (en) * | 2013-10-14 | 2015-04-29 | 北京大学 | Chemical synthesis method of neomangiferin and intermediate compounds of neomangiferin |
| CN104473875A (en) * | 2014-11-20 | 2015-04-01 | 广西中医药大学 | Multi-element mangiferin solid dispersion as well as preparation method and application thereof |
| US10538547B2 (en) | 2016-07-04 | 2020-01-21 | Changzhou Deze Medical Science Co., Ltd | Mangiferin-6-O-calcium salt and preparation process thereof |
| WO2018006737A1 (en) * | 2016-07-04 | 2018-01-11 | 常州德泽医药科技有限公司 | Mangiferin-6-o-calcium salt and preparation method and use thereof |
| US10537604B2 (en) | 2016-07-19 | 2020-01-21 | Nektium Pharma, S.L. | Compositions for enhancing brain activity |
| US11376294B2 (en) | 2016-07-19 | 2022-07-05 | Nektium Pharma S.L. | Mangiferin-containing compositions for improving sports performance |
| CN106727964A (en) * | 2016-12-16 | 2017-05-31 | 宁波沪信药物技术有限公司 | Composition of dibenzopyrans ketone and morphinane alkaloid and application thereof |
| CN106581161A (en) * | 2016-12-16 | 2017-04-26 | 宁波沪信药物技术有限公司 | Composition for treatment and prevention of abnormal glucose metabolism and use thereof |
| CN106491718A (en) * | 2016-12-16 | 2017-03-15 | 宁波沪信药物技术有限公司 | Produce compositionss from two kinds of plant amedica and application thereof |
| US10874708B2 (en) | 2017-01-10 | 2020-12-29 | Nektium Pharma, S.L. | Compositions for reducing appetite and craving, increasing satiety, enhancing mood, and reducing stress |
| US11141450B2 (en) | 2017-01-10 | 2021-10-12 | Nektium Pharma, S.L. | Compositions for reducing appetite and craving, increasing satiety, enhancing mood, and reducing stress |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008061480A1 (en) | Novel mangiferin calcium salts, the method for its preparation and its use | |
| US8334267B2 (en) | Mangiferin calcium salts, the method for its preparation and its use | |
| EP2444094A1 (en) | Mangiferin-berberine salt, manufacturing method and use thereof | |
| CN101732417B (en) | Preparation method and application of ion pair mixture of macleaya cordata total alkaloid | |
| US10285969B2 (en) | Mangiferin-6-O-berberine salt and preparation method and use thereof | |
| CN106995397B (en) | R-amisulpride medicinal salt, preparation method, crystal form and application thereof | |
| JP2019509332A (en) | Baicalin magnesium compound, its production method and use | |
| CN104557892A (en) | Mangiferin single-site derivative and preparation method and application thereof | |
| CN104447904B (en) | Stable gastrodine crystal that a kind of oral administration biaavailability is high and preparation method thereof, preparation and application | |
| CN111560044B (en) | 11-O-momordica grosvenori alcohol oxime ether derivative and preparation method thereof | |
| CN101848922B (en) | Novel mangiferin calcium salts, the method for preparation and use thereof | |
| WO2004039759A1 (en) | A natural compound useful for treating diabetes, its preparation and use | |
| CN110283166B (en) | Ethoxy bridged thiazole coumarin compound and preparation method and application thereof | |
| CN114315806B (en) | Preparation method of ester catechin-theanine adduct | |
| WO2021103749A1 (en) | Left-handed bicyclic morpholine and salt thereof, preparation method therefor, pharmaceutical composition, and application | |
| CN114644642A (en) | Crystal form A of thienopyridine compound, preparation method and pharmaceutical composition thereof | |
| CN110804026B (en) | Synthesis method of 1- (3- (3- (4-chlorphenyl) propoxy) propyl) piperidine hydrochloride | |
| CN111808095A (en) | Berberine-cinnamic acid derivative monocrystal, and preparation method and application thereof | |
| EP2716637B1 (en) | Mangiferin aglycone crystal form i and preparation method thereof | |
| CN109876022B (en) | Black fungus blood fat reducing active part and preparation method and application thereof | |
| CN112159448A (en) | Ethinylestradiol pharmaceutical co-crystal and preparation method and application thereof | |
| CN113461704B (en) | Monoterpene coumarin compound, preparation method and application thereof | |
| CN108530504B (en) | Compound and preparation method and application thereof | |
| CN116410201A (en) | Flavonoid compound extracted from black mulberry plants and preparation method and application thereof | |
| CN106974923B (en) | Preparation of Sutherlandin-5-cis-p-coumarate and application thereof in preparation of medicine for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07817302 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07817302 Country of ref document: EP Kind code of ref document: A1 |